Amyotrophic lateral sclerosis (ALS) is an intractable disease affecting the upper and lower motor neurons and resulting in progressive systemic muscle weakness and atrophy. The duration from symptom onset to the use of invasive respiratory support or death is 20 to 48 months.
1 Although riluzole
2,3 and edaravone
4 have been approved by the US Food and Drug Administration to modify the disease progression of ALS, the effectiveness of these drugs is restricted, warranting the development of further treatments.